Core Viewpoint - The stock of Aikang Medical (01789) has shown strong resilience and recovery in the Hong Kong stock market despite significant fluctuations since April, supported by solid financial performance and strategic shifts towards digital orthopedics and orthopedic surgical robots [1][2][5]. Financial Performance - Aikang Medical reported a revenue of 1.346 billion RMB for the fiscal year 2024, representing a year-on-year growth of 23.1% [1]. - The company's net profit attributable to equity shareholders reached 274 million RMB, an increase of 50.4% year-on-year [1]. - The revenue from joint products has seen a recovery due to the clearance of price reduction risks associated with centralized procurement [1][7]. Stock Market Activity - Southbound funds have increased their holdings in Aikang Medical from 16.73% on December 2 of the previous year to 21.61% by April 16 of this year, with the market value of these holdings rising to nearly 1.4 billion HKD [2][5]. - The stock price of Aikang Medical experienced a significant decline of 86.31% from its peak in July 2020 to a low in April 2022, but has shown signs of recovery since then [5][7]. Market Dynamics - The centralized procurement results for joint products have led to a price increase for most items, with procurement quantities rising by approximately 10% compared to the first round of procurement [6][7]. - Aikang Medical's market share in top hospitals has been increasing, with a reported 20% market share in the domestic market and a 19% share in the top 10 hospitals [7]. Industry Trends - The orthopedic surgical robot market is projected to grow significantly, with an expected market size of 70.952 billion RMB in China by 2030, reflecting a compound annual growth rate of 36.9% [8]. - Aikang Medical is positioned as a leading provider of comprehensive solutions in the digital orthopedic space, integrating various technologies to create a closed-loop system for joint implants [11][12]. Competitive Landscape - The domestic orthopedic surgical robot market is becoming increasingly competitive, with Aikang Medical facing competition from companies like MicroPort, Jianjia Medical, and Tianzhihang, which currently hold significant market shares [12]. - Despite the competitive environment, Aikang Medical is expected to leverage its strengths in digital orthopedics to enhance its market position and drive future growth [12].
集采风险逐步出清，重返双位数营收增长的爱康医疗(01789)踏上数字骨科风口